Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $255 | In Stock | |
5 mg | $668 | In Stock | |
10 mg | $1,070 | In Stock | |
25 mg | $1,590 | In Stock | |
50 mg | $2,130 | In Stock | |
100 mg | $2,890 | In Stock |
Description | Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN). |
In vivo | Treatment with Lirilumab (intravenous injection; once; 15 mg/kg) enhances the survival rate of mice injected with tumor[1]. |
Alias | ONO-4483, IPH2102 |
Molecular Weight | 145.52 kDa |
Cas No. | 1000676-41-4 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.